Discoveries, drugs and skeletal disorders

Nature Reviews Drug Discovery

Volumn 1, Issue 10, 2002, Pages 784-796

  Goltzman, David ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ADENOSINE TRIPHOSPHATASE INHIBITOR; ALENDRONIC ACID; ALFACALCIDOL; BENZOTHIOPHENE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CLODRONIC ACID; CYSTEINE PROTEINASE INHIBITOR; DISINTEGRIN; ESTRADIOL; ESTROGEN; ESTRONE; ETIDRONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; IDOXIFENE; LASOFOXIFENE; LEPTIN; NAPHTHALENE DERIVATIVE; PAMIDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TILUDRONIC ACID; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; ZOLEDRONIC ACID;

AGE; BONE DENSITY; BONE DISEASE; BONE MINERAL; BONE TURNOVER; CELL ACTIVITY; CHRONIC DISEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; FEMALE; HORMONE SUBSTITUTION; HUMAN; MALE; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PERIODONTAL DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS; ANIMAL; DRUG EFFECT; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACEUTICS; PHYSIOLOGY;

ANIMALS; BONE DISEASES; HUMANS; OSTEOBLASTS; OSTEOCLASTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036782072     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd916     Document Type: Review

References (119)

1. Cummings, S. R. & Melton, L. J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359, 1761-1767 (2002).
2. Doherty, D. A., Sanders, K. M., Kotowicz, M. A. & Prince, R. L. Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporosis Int. 12, 16-23 (2001).
3. Ray, N. F., Chan, J. K., Thamer, M. & Melton, L. J. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J. Bone Miner. Res. 12, 24-35 (1997).
4. Burr, D. B. The contribution of the organic matrix to bone's material properties. Bone 31, 8-11 (2002).
5. Kanis, J. A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359, 1929-1936 (2002).
6. Hunziker, E. B. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. Osteoarthritis Cartilage 10, 432-463 (2002).
7. Klareskog, L., Lorentzen, J., Padyukov, L. & Alfredsson, L. Genes and environment in arthritis: can RA be prevented? Arthritis Res. 4 (Suppl. 3), S31-936 (2002).
8. Goltzman, D., Karaplis, A. C., Kremer, R. & Rabbani, S. A. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 88 (Suppl. 12), 2903-2908 (2000).
9. Gemmell, E., Yamazaki, K. & Seymour, G. J. Destructive periodontitis lesions are determined by the nature of the lymphocytic response. Crit. Rev. Oral Biol. Med. 13, 17-34 (2002).
10. Reddy, S. V., Kurihara, N., Menaa, C. & Roodman, G. D. Paget's disease of bone: a disease of the osteoclast. Rev. Endocr. Metab. Disord. 2, 195-201 (2001).
11. Econs, M. J. New insights into the pathogenesis of inherited phosphate wasting disorders. Bone 25, 131-135 (1999).
12. White, K. E. et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nature Genet. 26, 345-348 (2000).
13. Mawer, E. B. & Davies, M. Vitamin D nutrition and bone disease in adults. Rev. Endocr. Metab. Disord. 2, 175-186 (2001).
14. Aubin, J. E. Regulation of osteoblast formation and function. Rev. Endocr. Metab. Disord. 2, 81-94 (2001).
15. Komori, T. et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755-764 (1997).
16. Nakashima, K. et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17-29 (2002).
17. Sabatakos, G. et al. Overexpression of ΔFOSB transcription factor(s) increases bone formation and inhibits adipogenesis. Nature Med. 6, 985-990 (2000).
18. Jochum, W. et al. Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nature Med. 6, 985-990 (2000).
19. Rouleau, M. F., Mitchell, J. & Goltzman, D. In vivo distribution of parathyroid hormone receptor in bone: evidence that a predominant osseous target cell is not the mature osteoblast. Endocrinology 123, 187-191 (1988).
20. Suda, T., Kobayashi, K., Jimi, E., Udagawa, N. & Takahashi, N. The molecular basis of osteoclast differentiation and activation. Novartis Found. Symp. 232, 235-247 (2001).
21. Watanuki, M. et al. Role of inducible nitric oxide synthase in skeletal adaptation to acute increases in mechanical loading. J. Bone Miner. Res. 17, 1015-1025 (2002).
22. Miao, D., He, B., Karaplis, A, C. & Goltzman, D. Parathyroid hormone is essential for normal fetal bone formation. J. Clin. Invest. 109, 1173-1182 (2002).
23. Amizuka, N. et al. Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev. Biol. 175, 166-176 (1996).
24. Miao, D. et al. Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. J. Biol. Chem. 276, 32204-32213 (2001).
25. Carpio, L., Gladu, J., Goltzman, D. & Rabbani, S. A. Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am. J. Physiol. Endocrinol. Metab. 281, E489-E499 (2001).
26. Jilka, R. L. et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104, 439-446 (1999).
27. Rodan, G. A. & Martin, T. J. Therapeutic approaches to bone diseases. Science 289, 1508-1514 (2000).
28. Dempster, D. W. et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 16, 1846-1853 (2001).
29. Canalis, E. Novel treatments for osteoporosis. J. Clin. Invest. 106, 177-179 (2000).
30. Gong, Y. et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513-523 (2001).
31. Little, C. D. et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70, 11-19 (2002).
32. Boyden, L. M. et al. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513-1521 (2002).
33. Kato, M. et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157, 303-314 (2002).
34. Mao, B. et al. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signaling. Nature 417, 664-667 (2002).
35. Hunter, I., McGregor, D. & Robins, S. P. Caspase-dependent cleavage of cadherins and catenins during osteoblast apoptosis. J. Bone Miner. Res. 16, 466-477 (2001).
36. Marie, P. J. Role of N-cadherin in bone formation. J. Cell. Physiol. 190, 297-305 (2002).
37. Lecanda, F. et al. Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J. Cell Biol. 151, 931-944 (2000).
38. Tanaka, Y. et al. H-Ras/mitogen-activated protein kinase pathway inhibits integrin-mediated adhesion and induces apoptosis in osteoblasts. J. Biol. Chem. 277, 21446-21452 (2002).
39. Bianco, P., Riminucci, M., Gronthos, S. & Robey, P. G. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 19, 180-192 (2001).
40. Nuttall, M. E. & Gimble, J. M. Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone 27, 177-184 (2000).
41. Capdevila, J. & Belmonte, J. C. Patterning mechanisms controlling vertebrate limb development. Annu. Rev. Cell Dev. Biol. 17, 87-132 (2001).
42. Garrett, I. R. & Mundy, G. R. The role of statins as potential targets for bone formation. Arthritis Res. 4, 237-240 (2002).
43. Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
44. Soriano, P., Montgomery, C., Geske, R. & Bradley, A. Targeted disruption of the c-Src proto-oncogene leads to osteopetrosis in mice. Cell 64, 693-702 (1991).
45. Sanjay, A., et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, αvβ3 integrin-mediated signaling, cell adhesion, and osteoclast motility. J. Cell Biol. 152, 181-196 (2001).
46. Hu, P. Y. et al. A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries. Hum. Mutat. 1, 288-292 (1992).
47. Teti, A. et al. Cytoplasmic pH regulation and chloride/bicarbonate exchange in avian osteoclasts. J. Clin. Invest. 83, 227-233 (1989).
48. Blair, H. C., Teitelbaum, S. L., Ghiselli, R. & Gluck, S. Ostoeclastic bone resorption by a polarized vacuolar proton pump. Science 245, 855-857 (1989).
49. Stroup, G. B. et al. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J. Bone Miner. Res. 16, 1747-1749 (2001).
50. Tondravi, M. M. et al. Osteopetrosis in mice lacking hematopoietic transcription factor PU. 1. Nature 386, 81-84 (1997).
51. Grigoriadis, A. E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448 (1994).
52. Iotsova, V. et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nature Med. 3, 1285-1289 (1997).
53. Hodgkinson, C. A. et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic helix-loop-helix zipper protein. Cell 74, 395-404 (1993).
54. Theill, L. E., Boyle, W. J. & Penninger, J. M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20, 795-823 (2002).
55. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
56. Takayanagi, H. et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408, 600-605 (2000).
57. Delmas, P. D. Treatment of postmenopausal osteoporosis. Lancet 359, 2018-2026 (2002).
58. Russell, R. G. et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J. Bone Miner. Res. 14 (Suppl. 2), 53-65 (1999).
59. Lehenkari, P. P. et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 61, 1255-1262 (2002).
60. Lindsay, R, Hart, D. M. & Fogelman, I. Bone mass after withdrawal of oestrogen replacement. Lancet 1, 729 (1981).
61. Manolagas, S. C., Kousteni, S. & Jilka, R. L. Sex steroids and bone. Recent Prog. Horm. Res. 57, 385-409 (2002).
62. Riggs, B. L., Khosla, S. & Melton, L. J. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23, 279-302 (2002).
63. Lufkin, E. G., Wong, M. & Deal, C. The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis. Rheum. Dis. Clin. North Am. 27, 163-185 (2001).
64. Martin, T. J. Calcitonin, an update. Bone 24 (Suppl. 5), 63S-65S (1999).
65. Nguyen, T. V. & Eisman, J. A. Genetics of fracture: challenges and opportunities. J. Bone Miner. Res. 15, 1243-1252 (2000).
66. Karsenty, G. & Wagner, E. F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell. 2, 389-406 (2002).
67. Kim, H. J., Rice, D. P., Kettunen, P. J. & Thesleff, I. FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. Development 125, 1241-1251 (1998).
68. Suda, N. et al. Parathyroid hormone-related protein is required for normal intramembranous bone development. J. Bone Miner. Res. 16, 2182-2191 (2001).
69. Zhang, X. et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J. Clin. Invest. 109, 1405-1415 (2002).
70. Bi, W. et al. Sox9 is required for cartilage formation. Nature Genet. 22, 85-89 (1999).
71. Smits, P. et al. The transcription factors L-Sox5 and Sox6 are essential for cartilage formation. Dev. Cell 1, 277-290 (2001).
72. Panda, D. K. et al. The transcription factor SOX9 regulates cell cycle and differentiation genes in chondrocytic CFK2 cells. J. Biol. Chem. 276, 41229-41236 (2001).
73. Amizuka, N., Warshawsky, H., Henderson, J. E., Goltzman, D. & Karaplis, A. C. Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J. Cell Biol. 126, 1611-1623 (1994).
74. Chung, U. I., Schipani, E., McMahon, A. P. & Kronenberg, H. M. Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. J. Clin. Invest. 107, 295-304 (2001).
75. Ornitz, D. M. & Marie, P. J. FGF signaling pathways in endochondral and intramembraneous bone development and human genetic disease. Genes Dev. 16, 1446-1465 (2002).
76. Zelzer, E. et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 129, 1893-1904 (2002).
77. St-Jacques, B., Hammerschmidt, M. & McMahon, A. P. Indian hedgehog signalling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13, 2072-2086 (1999).
78. Takeda, S. & Karsenty, G. Central control of bone formation. J. Bone Miner. Metab. 19, 195-198 (2001).
79. Panda, D. K. et al. Targeted ablation of the 25-hydroxyvitamin D1 α-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl Acad. Sci. USA 98, 7498-7503 (2001).
80. Amling, M. et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homaostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140, 4982-4987 (1999).
81. Mosekilde, L. Mechanisms of age-related bone loss. Novartis Found. Symp. 235, 150-166 (2001).
82. Norman, T. L. & Wang, Z. Microdamage of human cortical bone: incidence and morphology in long bones. Bone 20, 375-379 (1997).
83. Gazit, D., Zilberman, Y., Ebner, R. & Kahn, A. Bone loss (osteopenia) in old male mice results from diminished activity and availability of TGF-β. J. Cell. Biochem. 70, 478-488 (1998).
84. Aerssens, J., Boonen, S., Joly, J. & Dequeker, J. Variations in trabecular bone composition with anatomical site and age: potential implications for bone quality assessment. J. Endocrinol. 155, 411-421 (1997).
85. Seeman, E. Pathogenesis of bone fragility in women and men. Lancet 359, 1841-1850 (2002).
86. Delmas, P. D. et al. The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporosis Int. 13, 1-5 (2002).
87. The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276, 1389-1396 (1996).
88. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
89. Ettinger, B. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282, 637-645 (1999).
90. Barrett-Connor, E. et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287, 847-857 (2002).
91. Watts, N. B. Treatment of osteoporosis with bisphosphonates. Rheum. Dis. Clin. North. Am. 27, 197-214 (2001).
92. Hosking, D. et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N. Engl. J. Med. 338, 485-492 (1998).
93. Mortensen, L. et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J. Clin. Endocrinol. Metab. 83, 396-402 (1998).
94. Schnitzer, T. et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12, 1-12 (2000).
95. Cummings, S. R. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280, 2077-2082 (1998).
96. Harris, S. T. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282, 1344-1352 (1999).
97. Black, D. M. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348, 1535-1541 (1996).
98. McClung, M. R. et al. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344, 333-340 (2001).
99. Ringe, J. D., Orwall, E., Daifotis, A. & Lombardi, A. Treatment of male osteoporosis: recent advances with alendronate. Osteoporosis Int. 13, 195-199 (2002).
100. Saag, K. G. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292-299 (1998).
101. Reid, I. R. et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med 346, 653-661 (2002).
102. Siris, E. S. Goals of treatment for Paget's disease of bone. J. Bone Miner. Res. 14 (Suppl. 2), 49-52 (1999).
103. Coleman, R. E. Optimising treatment of bone metastases by Aredia and Zometa. Breast Cancer 7, 361-369 (2000).
104. Glorieux, F. H. et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339, 947-952 (1998).
105. Lehmann, H. J., Mouritzen, U., Christgau, S., Cloos, P. A. & Christiansen, C. Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann. Rheum. Dis. 61, 530-533 (2002).
106. Chesnut, C. H. et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. 109, 267-276 (2000).
107. Selye, H. On stimulation of new bone-formation with parathyroid extract and irradiated ergosterol. Endocrinology 16, 547-558 (1932).
108. Reeve, J. et al. The anabolic effect of low doses of human parathyroid hormone fragment on the skeleton in postmenopausal osteoporosis. Lancet 1, 1035-1038 (1976).
109. Tam, C. S., Heersche, J. N., Murray, T. M. & Parsons, J. A. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110, 506-512 (1982).
110. Dobnig, H. & Turner, R. T. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 138, 4607-4612 (1997).
111. Neer, R. M. et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441 (2001).
112. Brown, A. J. Therapeutic uses of vitamin D analogues. Am. J. Kidney Dis. 38 (Suppl. 5), S3-S19 (2001).
113. Dawson-Hughes, B., Harris, S. S., Krall, E. A. & Dallal, G. E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337, 670-676 (1997).
114. Chapuy, M. C. et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N. Engl. J. Med. 327, 1637-1642 (1992).
115. Negro-Vilar, A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J. Clin. Endocrinol. Metab. 84, 3459-3462 (1999).
116. Lieberman, J. R., Daluiski, A. & Einhorn, T. A. The role of growth factors in the repair of bone. Biology and clinical applications. J. Bone Joint Surg. Am. 84, A1032-A1044 (2002).
117. 2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 299, 323-331 (2001).
118. Meunier, P. J. et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 87, 2060-2066 (2002).
119. Reginster, J. Y. Strontium ranelate in osteoporosis. Curr. Pharm. Des. 8, 19079-1916 (2002).